Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

Completed

Conditions studied: Lymphoma, Mantle-Cell

In brief

The objective of this study is to determine the effectiveness of lenalidomide in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL) following ibrutinib treatment. MCL subjects who require treatment after receiving ibrutinib therapy are considered a population with high unmet medical need. It is therefore of benefit to have data on the outcomes of treatment options available in this patient population. An observational study design was chosen to collect the clinical data already existing or being collected for MCL subjects being treated with lenalidomide. MCL subjects who received lenalidomide either as monotherapy or as combination treatment after having relapsed or progressed on ibrutinib treatment or were refractory or intolerant to ibrutinib treatment are eligible for the study. Lenalidomide does not need to be the next subsequent treatment after ibrutinib.

Key facts

Study ID

NCT02341781

Run by

Celgene

People needed

30

Starts

2015-04-01

Expected to finish

2016-09-01

Last updated by the study team

2017-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Understand and voluntarily sign an informed consent document (ICD), if applicable, prior to any collection of study-related data.
• Males or females ≥ 18 years of age at the time of signing the ICD (if informed consent is applicable)
• Diagnosis of Mantle Cell Lymphoma (MCL) as assessed by the investigator. A copy of a pathology report establishing the diagnosis of MCL must be available
• Must have received at least one dose of ibrutinib and must have met at least one of the following criteria:
• A. Relapse: Subjects with relapse following initial response of CR to ibrutinib (or an ibrutinib-containing regimen). Subjects may have discontinued or completed ibrutinib treatment at the time of relapse, and there is no upper limit on the time between the last dose of ibrutinib to time of relapse. B. Progressive disease (PD): Subjects with PD following initial response of PR to ibrutinib (or an ibrutinib-containing regimen). Subjects may have discontinued or completed ibrutinib at the time of progression, and there is no upper limit on the time between the last dose of ibrutinib to time of progression. C. Refractoriness: Subjects with i. Best response of stable disease (SD) during treatment with ibrutinib (or an ibrutinib-containing regimen), and then subsequently had PD, or ii. Best response of PD at anytime while on ibrutinib (or an ibrutinib-containing regimen) D. Intolerance: Subjects requiring premature discontinuation of ibrutinib for reasons other than PD prior to the planned end of treatment. Potential reasons for premature discontinuation may include Adverse Event (AE) attributed to ibrutinib or inability to continue ibrutinib for other reasons. Subjects responding to ibrutinib treatment must have documented PD/relapse following discontinuation of ibrutinib. The reason for the premature discontinuation of ibrutinib will be recorded.

You may not qualify if…

• no exclusion criteria.

Where it is running

• Mayo Clinic Scottsdale — Phoenix, Arizona, United States
• Innovative Clinical Research Institute — Whittier, California, United States
• University of Miami and Sylvester Comprehensive Cancer — Miami, Florida, United States
• University of Michigan Comprehensive Cancer Center Division of Hematology Oncology — Ann Arbor, Michigan, United States
• Columbia Comprehensive Cancer Care Clinic — Jefferson City, Missouri, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Weill Cornell Medical College — New York, New York, United States
• Levine Cancer Institute — Charlotte, North Carolina, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Froedtert and The Medical College of Wisconsin — Milwaukee, Wisconsin, United States
• Universitatsmedizin der Johannes Gutenberg- Universitat — Mainz, Rhineland-Palatinate, Germany
• Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi — Bologna, Emilia-Romagna, Italy
• Derriford Hospital Plymouth Oncology Center Clinical — Plymouth, Devon, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.